Literature DB >> 17105491

The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.

M Schneider1, M Munder, S Karakhanova, A D Ho, M Goerner.   

Abstract

The mechanisms that induce and control the alloimmune inflammation of graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (allo-SCT) are still incompletely understood. In the murine system, GvHD can be suppressed by CD4(+)CD25(+) regulatory T cells (TREG), which are generally involved in the suppression of inflammatory reactions. A disruption of the homeostasis between TREG and conventional T cells might therefore be associated with the inflammatory reactions of GvHD. We repetitively measured the frequency of TREG in the peripheral blood of 29 patients within the first 71-373 days after allo-SCT and correlated the results with the clinical course. We demonstrate that the initial phase of GvHD is associated with a significant reduction of TREG in the peripheral blood, while at later stages and during intensified immunosuppressive therapy, increased numbers of TREG appear. These results might indicate a pathogenic role for reduced numbers of TREG in the induction of human GvHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105491     DOI: 10.1111/j.1365-2257.2006.00825.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  8 in total

1.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.

Authors:  James D Lord; Robert C Hackman; Ted A Gooley; Brent L Wood; Amanda C Moklebust; David M Hockenbery; Gideon Steinbach; Steven F Ziegler; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

2.  Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease.

Authors:  Zhenyi Jin; Xiuli Wu; Shaohua Chen; Lijian Yang; Qifa Liu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2014-01-11       Impact factor: 3.311

3.  Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Authors:  John M Magenau; Xuemei Qin; Isao Tawara; Clare E Rogers; Carrie Kitko; Matthew Schlough; Daniel Bickley; Thomas M Braun; Pil-Sang Jang; Kathleen P Lowler; Dawn M Jones; Sung W Choi; Pavan Reddy; Shin Mineishi; John E Levine; James L M Ferrara; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-17       Impact factor: 5.742

4.  Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells.

Authors:  J M Palmer; B J Chen; D DeOliveira; N-D Le; N J Chao
Journal:  Bone Marrow Transplant       Date:  2009-07-13       Impact factor: 5.483

5.  Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.

Authors:  Emilia Jaskula; Dorota Dlubek; Agnieszka Tarnowska; Janusz Lange; Monika Mordak-Domagala; Krzysztof Suchnicki; Mariola Sedzimirska; Agata Borowik; Sylwia Mizia; Andrzej Lange
Journal:  Viruses       Date:  2015-03-23       Impact factor: 5.048

Review 6.  T regulatory cells: aid or hindrance in the clearance of disease?

Authors:  Clint A Coleman; Michaela C Muller-Trutwin; Cristian Apetrei; Ivona Pandrea
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

Review 7.  Improving engraftment and immune reconstitution in umbilical cord blood transplantation.

Authors:  Robert Danby; Vanderson Rocha
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

8.  Prostaglandin E2 directly inhibits the conversion of inducible regulatory T cells through EP2 and EP4 receptors via antagonizing TGF-β signalling.

Authors:  Marie Goepp; Siobhan Crittenden; You Zhou; Adriano G Rossi; Shuh Narumiya; Chengcan Yao
Journal:  Immunology       Date:  2021-10-01       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.